source
- Vaxcyte's next-gen pneumococcal vaccine matches leading shots in Phase 3 trialVaxcyte reported that its experimental pneumococcal vaccine, VAX-31, achieved its primary efficacy goals in the first of three Phase 3 studies. In adults aged 50 and older, the vaccine performed o…
- Late-stage mRNA melanoma vaccine shows promise, slowing disease recurrenceA late-stage trial of an mRNA-based cancer vaccine reported that the treatment halted the return of melanoma in patients, providing the first clear evidence of efficacy for this approach. Merck an…